CN104784561A

CN104784561A - Medicine for treating lung cancer

Info

Publication number: CN104784561A
Application number: CN201510234510.XA
Authority: CN
Inventors: 顾克斌
Original assignee: Individual
Current assignee: Individual
Priority date: 2015-05-10
Filing date: 2015-05-10
Publication date: 2015-07-22

Abstract

The invention relates to a medicine for treating lung cancer. The medicine for treating the lung cancer is prepared from the following raw materials in parts by weight: 60 parts of herb of sessile skullcap, 50 parts of all-grass of yellow sweetclover, 45 parts of all-grass of chinling mountains gentian, 40 parts of root of girald jasmine, 40 parts of bulb of longroot onion, 40 parts of herb of milkywhite pearleverlasting, 40 parts of wildrice stem, 35 parts of common fenugreek seed, 30 parts of all-grass of beautiful flower saussurea, 30 parts of insingnis pulicaria, 25 parts of hairy raspberry and 20 parts of liquorice root. The medicine is prepared from pure traditional Chinese medicines; the characteristics, such as small toxicity and good curative effect, of natural medicines are achieved; and the curative effect is definite, and the lung cancer can be effectively treated.

Description

A kind of medicine for the treatment of pulmonary carcinoma

Technical field

The present invention relates to field of medicaments, specifically, relate to a kind of medicine for the treatment of pulmonary carcinoma.

Background technology

Along with the development of society and the quickening of urbanization process, the life of people becomes very convenient, but living environment is but subject to serious impact, the healthy of people in the serious threats such as air pollution, food pollution, pollution of waterhead, add the bad life habits such as smoking, increasing people have changed pulmonary carcinoma, and the M & M due to pulmonary carcinoma increases the fastest, to become one of population health and the maximum malignant tumor of life threat.The many countries of immediate and mid-term all report that the M & M of pulmonary carcinoma all obviously increases, and male lung cancer M & M all accounts for first of all malignant tumor, and women's sickness rate accounts for second, and mortality rate accounts for second.At present, the treatment means of pulmonary carcinoma is still based on excision, but postoperative multiplex relapse and metastasis, and mortality rate is high; Secondly, though radiation and chemotherapy can kill cancerous cell, also grievous injury normal structure simultaneously, toxic and side effects is large, patient suffering's degree is strong.

Summary of the invention

The object of this invention is to provide a kind of medicine for the treatment of pulmonary carcinoma.

In order to realize object of the present invention, the invention provides a kind of medicine for the treatment of pulmonary carcinoma, it is made up by weight of following bulk drugs: Herba Scutellariae Sessilifoliae 60 parts, melilotus 50 parts, the Herba Gentianae tsinglingensis 45 parts, Radix Jasmini Giraldii 40 parts, Bulbus Allii Victorialis 40 parts, Herba Anaphalidis Lacteae 40 parts, Caulis Zizaniae caduciflorae 40 parts, Semen Trigonellae 35 parts, beautiful hieracioides 30 parts, Pulicaria insignis Drumm. 30 parts, peritricha Fructus Rubi corchorifolii Immaturus 25 parts and 20 parts, Radix Glycyrrhizae.

Preferably, described medicine is tablet, dispersible tablet, decoction or capsule.

In the present compositions, Herba Scutellariae Sessilifoliae, melilotus are monarch drug, and the Herba Gentianae tsinglingensis, Radix Jasmini Giraldii, Bulbus Allii Victorialis, Herba Anaphalidis Lacteae are ministerial drug, and Caulis Zizaniae caduciflorae, Semen Trigonellae, beautiful hieracioides, Pulicaria insignis Drumm., peritricha Fructus Rubi corchorifolii Immaturus are adjuvant drug, and Radix Glycyrrhizae is for making medicine.

Medicine of the present invention is with pure traditional Chinese medicine, and keep little, the eutherapeutic characteristic of natural drug toxicity, clear curative effect, can treat pulmonary carcinoma effectively.

Detailed description of the invention

Below by way of the description of detailed description of the invention, the invention will be further described, but this is not limitation of the present invention, those skilled in the art are according to basic thought of the present invention, various amendment or improvement can be made, but only otherwise depart from basic thought of the present invention, all within the scope of the present invention.

The preparation of embodiment decoction of the present invention

Take Herba Scutellariae Sessilifoliae 60 grams, melilotus 50 grams, the Herba Gentianae tsinglingensis 45 grams, Radix Jasmini Giraldii 40 grams, Bulbus Allii Victorialis 40 grams, Herba Anaphalidis Lacteae 40 grams, Caulis Zizaniae caduciflorae 40 grams, Semen Trigonellae 35 grams, beautiful hieracioides 30 grams, Pulicaria insignis Drumm. 30 grams, peritricha Fructus Rubi corchorifolii Immaturus 25 grams and 20 grams, Radix Glycyrrhizae, be placed in 9000 ml waters, reflux 3 hours, filter, obtain filtering residue and filtrate, namely described filtrate obtain decoction of the present invention.

Experimental example

Diagnostic criteria

According to clinical symptoms, sign and imaging examination, the one meeting following situations can be used as clinical diagnosis:

1, chest X-ray finds Pulmonary Isolated Nodules or swollen thing, jagged;

2, pulmonary high-risk group, has cough or bloody sputum, and chest X-ray finds Focal lesion, through positive antiinflammatory or antituberculosis therapy (2 weeks-4 weeks) invalid or pathological changes increase person;

3, segmental pneumonia developed into segmental atelectasis in 2 months-3 months, or segmental atelectasis develops into full pulmonary atelectasis in a short time;

4, occur the side growth property bloody pleural fluid without other reasons in a short time, or side volume bloody pleural fluid accompanies pulmonary atelectasis person or pleural nodulations shape changer simultaneously;

5, obviously cough, out of breath, the two lung millet appearance of chest films showed or diffuse lesion, can get rid of Military tuberculosis, pulmonary metastases, pulmonary mycosis person;

6, rabat finds pulmonary lump, with hilus pulumonis or vertical phrenic lymph nodes enlargement, and occurs that superior vena cava blocks, recurrent nerve paralysis symptom, or with metastasis shower.

7, cough but no phlegm or few expectorant, or sputum mixed with blood, very then spit blood more than, chest pain, vexed difference of sleeping, low grade fever night sweat, or the strong Sheng of calorific potential, checks for a long time and do not move back, thirsty, constipation with dry stool, red tongue, and yellow fur, thready and rapid pulse or number are greatly.

Selector close standard of stating patient 80 example, wherein, man 50 example, female 30 example, minimum 39 years old of age, maximum 63 years old, average 52 years old.

Take the decoction prepared in embodiment to treat, three times on the one, each 100 milliliters.Continuous treatment 70 days.

The standard of curative effect evaluation

According to Short-term, appraisal of life quality 2 indexs, observe therapeutic effect.

1. Short-term criterion of therapeutical effect: according to the objective efficacy assessment standard of WHO treatment of cancer (Chinese Anti-Cancer Association. newly organized common pernicious pulmonary carcinoma diagnosis and treatment specification primary bronchogenic carcinoma of lung fascicle [S]. Beijing: combined publication society of China Concord Medical Science University of Beijing Medical University .1999:14-26.541.), different by treatment pulmonary carcinoma size variation, curative effect is divided into 4 grades.1. complete incidence graph: pulmonary carcinoma focus disappears completely and at least maintains more than 4 weeks; 2. partial rcsponse: the maximum gauge of pulmonary carcinoma focus and the product of maximum perpendicular transverse diameter reduce >=and 50%, and maintain more than 4 weeks, occur without new focus; 3. stablize: two footpath products of swollen lame focus reduce <50%, increase <25%, maintain more than 4 weeks, occur without new focus; 4. progress is worsened: pulmonary carcinoma increases >=25% or occur new focus.

2. appraisal of life quality: by Ka Shi standards of grading (look into people person of outstanding talent. modern pulmonary cancer diagnosis and treatment (M) .2 version. Beijing: People's Medical Officer Press .1999:416), after treatment, rising 10 is divided into effectively, it is invalid that decline 10 is divided into, and it is stable for being elevated between 10 points.

Therapeutic outcome

1. Short-term: complete incidence graph 38 example, partial rcsponse 27 example, stablizes 15 examples, worsens progress 0 example.

2. Ka Shi scoring after quality of life treatment, effective 53 examples of therapeutic effect, therapeutic effect stablizes 27 examples, invalid 0 example of therapeutic effect.

Untoward reaction and toxic and side effects supervision

By detect patient blood pressure, pulse, whether there is Nausea and vomiting, dizzy clinical symptoms judges untoward reaction.Find that the systolic pressure of all patients is between 90-140mmHg, diastolic pressure is between 60-90mmHg, and pulse is 60-100 beat/min, and blood pressure and pulse all within normal range, and does not occur Nausea and vomiting, dizzy clinical symptoms.This illustrates that pharmaceutical composition of the present invention does not have obvious untoward reaction, and then proves that this medicine does not have obvious toxic and side effects for human body.

Claims

1. treat the medicine of pulmonary carcinoma for one kind, it is characterized in that, it is made up by weight of following bulk drugs: Herba Scutellariae Sessilifoliae 60 parts, melilotus 50 parts, the Herba Gentianae tsinglingensis 45 parts, Radix Jasmini Giraldii 40 parts, Bulbus Allii Victorialis 40 parts, Herba Anaphalidis Lacteae 40 parts, Caulis Zizaniae caduciflorae 40 parts, Semen Trigonellae 35 parts, beautiful hieracioides 30 parts, Pulicaria insignis Drumm. 30 parts, peritricha Fructus Rubi corchorifolii Immaturus 25 parts and 20 parts, Radix Glycyrrhizae.

2. the medicine for the treatment of pulmonary carcinoma according to claim 1, is characterized in that, described medicine is tablet, dispersible tablet, decoction or capsule.